Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors (scientific article)

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Q27851529

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

Q28244895

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

Q29615366

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Q29617457

Initial treatment patterns over time for anaplastic oligodendroglial tumors

Q30419123

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

Q30426724

Survey of treatment recommendations for anaplastic oligodendroglioma

Q30441461

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Q30542081

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

Q33247166

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

Q33264150

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Q33531623

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Q34018659

Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older

Q34239869

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

Q34308674

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Q34446549

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EOR

Q34523475

Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis

Q35800783

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

Q36236484

Molecular subclassification of diffuse gliomas: seeing order in the chaos

Q37858944

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

Q37940126

Interlaboratory comparison of IDH mutation detection.

Q38077475

Molecular neuro-oncology in clinical practice: a new horizon

Q38125031

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

Q38129238

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

Q40008535

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

Q43081541

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

Q43245397

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Q45953731

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

Q48286137

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

Q48374829

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma

Q48465762

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Q48493738

What is an oligodendroglioma?

Q48629204

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Q48629888

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Q48824616

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

Q58003101

P433

issue

P921

main subject

oligodendrocyte

Q916698

P304

page(s)

1541-1546

P577

publication date

2014-07-04

P1433

published in

Neuro-Oncology

Q15724471

P1476

title

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors

P478

volume

Reverse relations

cites work (P2860)

Q38456018	Anaplastic glioma: current treatment and management
Q48822128	Personalized medicine in neuro-oncology
Q38666584	Statistical considerations on prognostic models for glioma
Q38684835	Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas
Q48250296	Success at last: a molecular factor that informs treatment